Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC - Autism Pilot Study
NCT05602116Phase 1Completed
- Sponsor
- Cell to Cure
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Cell2Cure in Autism Spectrum Disorder (ASD) and leaky gut syndrome (LGS), sponsored by Cell to Cure. Primary endpoint: Safety of C2C_ASC (Adverse Events) at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
Cell2Cure
03
Conditions
Autism Spectrum Disorder (ASD)leaky gut syndrome (LGS)
Beyond the preview
Go deeper on NCT05602116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602116.